| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143863 | Lung Cancer | 2007 | 7 Pages |
Abstract
This study strongly suggests that cisplatin, etoposide and irinotecan combination is very effective for the treatment of E-SCLC with good safety profile. The triplet regimen currently seems a promising regimen and has to be further explored in phase III trials.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
D. Pectasides, E. Samantas, G. Fountzilas, E. Briasoulis, P. Kosmidis, D. Skarlos, M.A. Dimopoulos, H.P. Kalofonos, T. Economopoulos, K. Syrigos,